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Zoledronic acid to prevent bone loss in the first 6 months after Renal transplantation is the treatment of choice for
renal transplantation. end-stage renal failure. However, post-transplant osteo-
Background. Bisphosphonates can prevent bone mineral dystrophy is a major problem, especially in the firstdensity loss after renal transplantation, but their effect on tra-
months after transplantation, because about 10% of bonebecular mineralization and bone morphology, two key factors
density is lost during this period [1]. The bone disease isof bone stability, remains unknown.
Methods. In a 6-month, randomized, placebo-controlled multifactorial and resembles a mixture of pathophysio-
study, 20 kidney transplant recipients received either 4 mg logically different entities. Pre-existing causes of osteo-
zoledronic acid or placebo twice within 3 months after en-
dystrophy are secondary hyperparathyroidism, vitamingraftment. At transplantation and after 6 months, mean trabec-
D metabolic disorders, parathyroid hormone resistanceular calcium concentration and trabecular morphometry were
measured in bone biopsies. Bone mineral density (BMD) of of bone cells, patient immobility, hypogonadism, amy-
the femoral neck and the lumbar spine were evaluated by dual- loidosis, or aluminum toxicity [2]. Furthermore, steroid
energy x-ray absorptiometry, and serum biochemical markers or immunosuppressive treatment of underlying renal dis-of bone metabolism were determined monthly.
ease, and long-term use of loop diuretics contribute toResults. Trabecular calcium content increased significantly
bone loss [3]. In addition, the main cause of terminalin the zoledronic acid group, but remained unchanged in the
placebo group. BMD at femoral neck showed no change in renal failure is diabetic nephropathy, and diabetes itself
the zoledronic acid group, but decreased in the placebo group. causes osteoporosis [4]. Some of these factors cease after
BMD of the lumbar spine was increased in the zoledronic acid
successful renal transplantation, but new, and even worse,group without change in the placebo group. High-turnover
causes of osteodystrophy arise. Among these are highbone disease resolved similarly in both groups, as evidenced
by a significant decrease of eroded bone surface, osteoclast steroid doses in the immediate post-transplant period,
and osteoblast surface. Serologic markers of bone formation calcineurin antagonist type of immunosuppression, renal
and resorption were significantly lower in zoledronic acid- tubular impairment of calcium and phosphorus reab-treated patients throughout the study. Kidney transplant func-
sorption, and the aggravation of the metabolic distur-tion was stable after zoledronic acid therapy.
bances in diabetic patients.Conclusions. Our results show that administration of zole-
dronic acid improves the calcium content of cancellous bone Early, as well as late, post-transplant bone loss has
after kidney transplantation. The beneficial effect of bisphos- been studied thoroughly by densitometry and bone mor-
phonate therapy is further evidenced by an increase of lumbar
phometry in children and adults [5, 6]. Changes in bonespine BMD, and stabilization of femur BMD.
architecture, however, have been investigated only in
two small studies. Julian et al [1] reported sequential
changes in bone morphology in 20 young patients with-
out diabetes and major comorbidity, and more than one
half of these patients had been transplanted preemp-Key words: zoledronic acid, renal transplantation, biopsy, bone miner-
alization, morphometry. tively. Even in this best-case scenario, histomorphometry
revealed an imbalance in bone remodeling caused by aReceived for publication May 22, 2002
decreased rate of bone formation and prolonged forma-and in revised form July 18, 2002, and September 24, 2002
Accepted for publication October 16, 2002 tion periods [1]. Briner et al [7] investigated the bone-
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with sequential transiliac crest biopsies and found an METHODS
increase in cancellous bone volume, but no resolution Patients
of metabolic bone abnormalities 2 years after trans- We consecutively recruited 28 adult hemodialysis pa-
plantation. tients, who received their first or second cadaveric renal
Several investigators conducted prospective treatment allograft. Patients were enrolled independently of the
studies in patients with post-transplant osteodystrophy, cause of renal failure, time on renal replacement therapy,
but used only densitometry or biochemical markers of or bone disease. Hemodialysis was performed in all pa-
bone turnover as a treatment outcome variable. Densi- tients according to the Dialysis Outcome Quality Initia-
tometry and biochemical markers, however, are not suit- tive (DOQI) guidelines [22]. Out of the 28 patients en-
able to uncover morphologic-architectural changes and rolled, 24 received 0.25 to 0.5 g 1,25 (OH)2 vitamin
D3 per day. Patients who had had previous or currentare only of moderate value to discriminate between the
treatment with either calcitonin or bisphosphonates, orvarious causes of renal osteodystrophy and to define
with hypocalcemia, were excluded from the study.patients at risk for fractures [8–10]. Therefore, more
sensitive methods of bone mineralization and bone archi-
Procedurestecture measurements such as bone mineralization den-
The study protocol was approved by the Institutionalsity distribution measurement (BMDD) (i.e., the degree
Review Board and each patient provided informed con-of trabecular calcium content in a given bone specimen
sent. Twenty of the 28 enrolled patients, who met theand bone morphometry) are necessary to guide thera-
inclusion criteria of serum creatinine below 2 mg/dLpeutic intervention and evaluate treatment success. The
within 2 weeks after transplantation, and a representa-diverse pathophysiologic entities of the skeletal changes
tive bone biopsy core obtained during the transplantallow discrimination between morphologically distinctly
procedure, were randomly assigned to an intravenous
different types of renal osteodystrophies [8, 11]. The infusion of 4 mg zoledronic acid or placebo in 250 mL
mineralization density and distribution can be evaluated saline over 15 minutes. Eight of the 28 patients did not
on bone biopsy specimen by quantitative backscattered meet the study inclusion criteria. Two patients died
electron imaging, a method that has been proved to within the first week after transplantation due to cardiac
be sensitive in the detection of small changes in the arrest, four patients had a serum creatinine above 2
mineralization pattern due to bisphosphonate treatment mg/dL 2 weeks after transplantation, the bone biopsy
of patients and in animal studies [12–14]. Furthermore, specimen was not adequate in one patient, and one pa-
BMDD allows discrimination between changes in bone tient withdrew consent before the first zoledronic acid/
volume and the degree of mineralization, which is not placebo infusion.
possible with conventional x-ray densitometry. Hence, A second infusion at the same dose was administered
3 months later. Therapy and randomization were sup-it is possible that x-ray densitometry reveals high bone
plied by Novartis (Basel, Switzerland). All patients re-mass in regions of reduced bone matrix mineralization
ceived 1000 mg of daily calcium citrate, but no vitaminand thus impaired mechanical stability.
D supplementation (Maxi-Kalz, Asta Medica, Vienna,The new bisphosphonate zoledronic acid (Zometa,
Austria). The immunosuppressive regimen consisted ofNovartis, Basel, Switzerland) potently inhibits osteoclas-
methylprednisolone, mycophenolate mofetil, and cyclo-tic bone resorption and has been shown to prevent osteo-
sporine. Two patients in the placebo group and one pa-porosis associated with estrogen deficiency, and halt pro-
tient in the zoledronic acid group received tacrolimusgression of osteolysis [15–17]. Zoledronic acid has not
instead of cyclosporine.been investigated for corticosteroid-induced osteoporo-
Bone histology and histomorphometry were per-sis, but convincing data are available for other bisphos-
formed on transcortical bone biopsies obtained from the
phonates, such as etidronate [18]. Besides the reduction
iliac crest during and 6 months after kidney transplanta-
of bone turnover, zoledronic acid has been shown to tion as described by Bordier, Miravet, and Hioco [23],
directly decrease type II collagen degradation in patients using the Meunier Bone Biopsy device (luminal diameter
with Paget’s disease [19]. Zoledronic acid is two to three 7 mm  0.28 inch; Groupe Le´pine, Lyon, France). Due
orders of magnitude more potent than pamidronate in to the design of the study (cadaver kidney transplanta-
bone resorption assays, but showed a threefold greater tion), the time point of transplantation was unknown
renal tolerability [20, 21]. and, thus, tetracycline labeling was not feasible. The
So far, no controlled study on the effect of bisphospho- specimens were then undecalcified embedded in plastic
nate therapy on bone morphology and mineralization and cut into 5 m thick sections. After standard staining,
density distribution for the prevention of post-transplant histologic analysis was performed by one pathologist
(G.D.), who was blinded for the clinical and biochemicalosteopathy exists.
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status, as well as the randomization group of the patients. Blood samples for biochemical bone markers were
drawn immediately before transplantation and monthlyRenal osteodystrophy was classified according the Del-
ling criteria, as reported previously [11]. By these criteria during follow up in all twenty patients. Bone alkaline-
phosphatase was measured by immunosorbent enzyme-three different groups of renal osteodystrophy are identi-
fied (types I, II, and III). If compared to the classification linked assay (ELISA), osteocalcin, intact parathyroid
(iPTH) and type I collagen peptides (crosslaps) by elec-of Malluche and Faugere [24], renal osteodystrophy type
II would equal osteomalacic low-turnover bone disease tro-chemiluminiscence and 1,25(OH)2 D3 by a radio-
immuno assay.and renal osteodystrophy type III would equal predomi-
nant hyperparathyroid, or high-turnover bone disease.
Statistical analysisMixed uremic osteodystrophy would spread over both
groups depending of whether osteoidosis (renal osteo- All results are expressed as mean  SE or median
and range when appropriate. Sample size calculationdystrophy type II) or osteoidosis and fibroosteoclasia
(renal osteodystropy type III) predominates. Renal os- revealed a minimum of 10 patients in each group to
detect a 2% difference in mean BMDD giving an  ofteodystrophy type I is mainly characterized by fibro-
osteoclasia and bone marrow fibrosis and was not present 0.05 and   0.8. We estimated that 80% of patients
would meet the inclusion criteria and post-randomiza-in any of our patients. Three-dimensional morphometric
analysis was carried out as described previously [11]. tion discontinuation rate would be 10%.
Either the two-tailed Student t test for paired data orAccording to Parfitt et al [25], the following parameters
were evaluated: trabecular bone volume and osteoid vol- the non-parametric Wilcoxon sign rank test was used for
differences in the same group at different time points.ume, both expressed as the percentage of tissue volume;
osteoid surface, expressed as the percentage of trabecu- The Student t test for unpaired data or the Mann-Whit-
ney U test were used for differences between the groups.lar bone surface; osteoblast surface; expressed as the
osteoid surface covered with osteoblasts, and as percent- Bonferroni-Holm correction was used for multiple com-
age of trabecular bone surface; osteoclast surface, ex- parisons. To evaluate the difference in trabecular cal-
pressed as the osteoid surface covered with osteoclasts, cium concentration between the zoledronic acid and pla-
and as the percentage of trabecular bone surface; and cebo group at 6 months, a multiple linear regression
eroded surface, expressed as percentage of trabecular model adjusted for baseline differences was used. A P
bone surface. value 0.05 was considered statistically significant.
Measurements of BMDD were performed using a
quantitative backscattered electron imaging method de-
RESULTSscribed previously [12, 14]. This method is based on the
Baseline characteristics were similar in both treatmentphenomenon that the backscattering coefficient of the
groups, with the exception of BMDD and osteoclastelectrons is dependent on the atomic number of the tar-
surface. Six patients withdrew their consent for a secondget material. In the case of bone tissue the backscattered
biopsy, thus only 14 bone biopsies were performed atelectron signal is directly proportional to the mineral
the end of the study. One of the second bone biopsycontent (calcium content) of the tissue. BMDD was
specimens contained mainly callous bone, possibly afterquantified by the BMDD-parameter Camean, describing
a foregoing microtrauma and was not suited for furtherthe weighted mean calcium (Ca) concentration of the
analysis. In summary, a total of seven (pre- and post-)imaged bone area. The full width at half maximum of
specimens were available from the zoledronic acid group,the peak is a measure of the homogeneity of the distribu-
and six (pre- and post-) specimens from the placebotion. All measurements were blinded for quantitated
group. Therefore, baseline and 6 months’ data on bonebackscattered electron imaging, histomorphometric, and
morphology and BMDD are given only for these 13biochemical analysis.
patients. The cumulative dose of methylprednisolone inBone mineral density measurements (BMD) were per-
the first 6 months after transplantation averaged 2.9 formed with dual-energy x-ray absorptiometry and a
0.4 g in the 10 placebo patients and 3.0  0.8 g in theQDR-4500 scanner (Hologic, Waltham, MA, USA), using
10 zoledronic acid-treated patients. In the six placebothe manufacturer’s recommended standard procedures
and seven zoledronic acid patients with complete bonefor the posteroanterior lumbar spine at L1-L4, and for
biopsy studies, the methylprednisolone doses were 2.4 the proximal femur at the femoral neck, trochanter, in-
0.7 and 2.7  0.6 g respectively.tertrochanteric region, total region, and Ward’s triangle.
Distribution of renal osteodystrophy was similar inThe projectional BMD values were given in grams per
both groups at baseline (Table 1). Histomorphologic fea-centimeter squared, and the individual patient’s results
tures of high-turnover bone disease diminished within 6were expressed as z scores and t scores. The diagnostic
months after transplantation as evidenced by a signifi-bone-mass threshold for defining osteoporosis in individ-
uals without fractures was set at a t score less than –2.5. cant decline of eroded surface, osteoblast surface, and
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Table 1. Patients characteristics at baseline
Placebo Placebo Zoledronic acid Zoledronic acid
(All patients) (With two bone biopsies) (All patients) (With two bone biopsies)
Mean age (SE) 49 (16) 54 (5) 55 (18) 58 (3)
Sex f/m 4/6 3/3 4/6 1/6
Kidney disease
Diabetic nephropathy 1 5 4
Polycystic kidney disease 2 1
Focal-segmental glomerulosclerosis 3
Henoch-Scho¨nlein purpura 1
Unknown 6 6 2 2
Number of first/second transplantation 9/1 5/1 8/2 6/1
Mean months on renal replacement therapy (SE) 32 (10) 40 (11) 43 (14) 40 (7)
Renal osteodystrophy (type II/type III) 3/7 1/5 3/7 2/5
osteoclast surface in both groups (Table 2). Although Osteocalcin, type I collagen peptides (crosslaps), and
mean osteoblast surface and osteoclast surface was com- iPTH decreased rapidly after transplantation. Osteocal-
parable between the groups, osteoid surface had in- cin and type I collagen peptides (crosslaps), indicators of
creased significantly in patients receiving zoledronic acid increased bone formation and resorption, respectively,
but remained unchanged in untreated patients (Table were significantly lower in patients receiving zoledronic
2). No biochemical or clinical evidence of osteomalacia (Fig. 1). Intact PTH levels were slightly higher in the
could be detected in the zoledronic acid-treated patients. placebo group at transplantation, but similar in both
Adynamic bone disease in the zoledronic patients could groups during monthly follow-up. Alkaline phosphatase,
be ruled out because unlike osteomalacia, the histopa- as a marker for osteoblast activity, was slightly but non-
thology of adynamic bone disease does not include an significantly, higher in the placebo group and did not
increase in osteoid formation. differ from baseline values in either group. 1,25(OH)2
There was a significant difference of mean trabecular vitamin D3 plasma levels increased as expected in both
calcification (Camean) between both groups at baseline, groups after transplantation (placebo, 10  3 vs. 27  9
with a higher concentration in patients who were going pg/mL, P  0.05; and zoledronic acid, 8  3 vs. 13  10
to receive zoledronic acid. However, at the end of pg/mL, P  NS). Renal function did not change after
the study, trabecular calcium content had only increased zoledronic acid infusion. Serum creatinine baseline val-
in zoledronic acid-treated patients and remained un- ues and values at 6 months were similar within the
changed in the placebo group (Table 2). Multiple linear groups, as well as between the groups (placebo vs. zole-
regression revealed a significant correlation between dronic acid 2 weeks after transplantation, 1.4  0.9 vs.
baseline values and Camean at 6 months (P 0.03). When 1.5  0.6 mg/dL; 6 months after transplantation, 1.5 
adjusted for baseline differences in Camean between the 0.1 vs. 1.4  0.1 mg/dL). No differences between the
zoledronic acid and placebo group, the difference at 6 groups could be observed in the baseline values of cal-
months failed to reach statistical significance (P  0.08). cium (placebo, 10  0.4 vs. zoledronic acid, 9.2  0.4
The full width at half maximum of the peak did not show mg/dL) and phosphorus (placebo, 6.2  0.6 vs. zole-
any significant difference between the zoledronic acid- dronic acid, 5.9  0.6 mg/dL). The respective values at
treated and non-treated group at baseline and at 6 6 months were calcium (placebo, 10  0.8 vs. zoledronic
months, suggesting a homogenous distribution of trabec- acid, 9.6  0.4 mg/dL) and phosphorus (placebo, 2.8 
ular calcification. 0.3 vs. zoledronic acid, 2.5  0.3 mg/dL).
Dual-energy x-ray absorptiometry measurements were
available from all patients at transplantation and after
DISCUSSION6 months. Mineral content of lumbar spine (g/cm2) and
This study demonstrates that two intravenous infu-z score improved significantly in patients receiving zole-
sions of the bisphosphonate zoledronic acid preventeddronic acid. In contrast, in placebo-treated patients,
post-transplant bone loss by increasing average trabecu-BMD of lumbar spine deteriorated significantly (Table
lar calcium concentration (Camean) in renal allograft recip-2). Dual-energy x-ray absorptiometry of the femur re-
ients in the first 6 months after successful transplantation.vealed a significant decrease of BMD of the femoral
The weight fraction of mean trabecular calcium in-neck, the Ward‘s triangle, and trochanter in the placebo
creased by 2% in the zoledronic acid group, but wasgroup, but not in patients receiving zoledronic acid.
unchanged in the placebo group. Between group differ-BMD of the intertrochanteric region remained un-
changed in both groups (Table 2). ences at 6 months were not statistically significant after
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Table 2. Mean (SE) values of histomorphometry, bone mineralization density distribution, and bone mineral density in zoledronic acid and
placebo-treated patients
Base Line 6 Months
Normal
Placebo Zoledronic acid Placebo Zoledronic acid values
Histomorphometry N  6 N  7 N  6 N  7
Bone volume (BV/TV) % 25 (2) 23 (2) 26 (1) 19 (2) 21 (1)
Osteoid volume (OV/TV) % 1.4 (0.6) 1.3 (0.5) 2.2 (0.6) 2.0 (0.6) 2.7 (0.4)
Osteoid surface (OS/BS) % 48 (9) 47 (8) 53 (4) 64 (6)a 14 (2)
Osteoblast surface (Ob.S/BS) % 7.6 (1.5) 4.4 (1.4) 2.6 (1.3)a 1.4 (0.9)a 4.9 (0.3)
Osteoclast surface (Oc.S/BS) % 3.2 (0.6) 1.5 (0.3)b 0.4 (0.3)a 0.6 (0.4)a 0.6 (0.02)
Eroded surface (ES/BS) % 16.8 (3.1) 10.7 (0.8) 5.9 (0.9)a 5.0 (1.0)a 3.6 (0.2)
Bone mineralization density distribution N  6 N  7 N  6 N  7
CaMean (wt %) 21.5 (0.2) 21.8 (0.1)b 21.4 (0.2) 22.2 (0.2)a,b 22.2 (0.3)
Bone mineral density N  10 N  10 N  10 N  10
Lumbar spine g/cm2 0.96 (0.04) 0.88 (0.05) 0.93 (0.04)a 0.91 (0.06)a
Lumbar spine z score 	0.47 (0.42) 	0.96 (0.03) 	0.74 (0.44)a 	0.73 (0.37)a
Femoral neck g/cm2 0.74 (0.03) 0.68 (0.04) 0.71 (0.03) 0.66 (0.04)
Femoral neck z score 	0.75 (0.36) 	1.15 (0.32) 	1.11 (0.93)a 	1.17 (0.34)
Trochanter g/cm2 0.66 (0.03) 0.59 (0.03) 0.63 (0.03)a 0.57 (0.03)
Trochanter z score 	0.55 (0.33) 	0.98 (0.23) 	0.78 (0.33)a 	1.19 (0.25)
Intertrochanteric region g/cm2 1.02 (0.04) 0.92 (0.04) 1.00 (0.05) 0.93 (0.04)
Intertrochanteric region z score 	0.69 (0.31) 	1.18 (0.21) 	0.73 (0.39) 	1.06 (0.25)
Ward’s triangle g/cm2 0.61 (0.05) 0.52 (0.03) 0.56 (0.05) 0.49 (0.03)
Ward‘s triangle z score 	0.18 (0.39) 	0.56 (0.26) 	0.64 (0.38)a 	0.64 (0.26)
a Indicates significant difference vs. baseline; b Indicates difference between placebo and zoledronic acid
Fig. 1. Time course of biochemical markers of bone formation and resorption in 10 zoledronic acid and 10 placebo-treated renal transplant
recipients. The hatched areas indicate the reference range. Symbols are: () alkaline phosphatase placebo and () zoledronic acid-treated patient
groups. Abbreviations are: CTX, type I collagen peptides (crosslaps); bone AP, alkaline phosphatase; iPTH, intact parathyroid gland.
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adjustment of the multiple linear regression model for thus argues strongly against osteomalacia in the zole-
baseline differences in Camean. The likeliest explanation dronic acid group. Adynamic bone disease could be ex-
for the mean difference in baseline Camean of 0.3 weight pelled by the increase of osteoid in the zoledronic acid
% after randomization is the relatively small sample size group. Markers of high turnover bone disease such as
of the study. The increase in Camean from 21.8 to 22.2 osteoblast and osteoclast surface and eroded surface im-
weight % in the zoledronic acid group seems low, but proved significantly within the first 6 months after en-
given the small intra- and interassay variations of 0.27 graftment in both patient groups, which can be attributed
and 0.30%, respectively, are statistically significant. Fur- to the reduction of the secondary hyperparathyroidism
thermore, zoledronic acid treatment led to an increase after successful renal transplantation in both groups.
of Camean close to the reference range, which was deter- Our findings support the hypothesis of investigators
mined post-mortem in 20 individuals of wide age range from previous studies, that third-generation bisphospho-
distribution without bone disease, who died in accidents nates lead to an increase of cancellous bone formation
[12]. Osteoid surface increased by 39% in the zoledronic [31, 32]. This could so far only be measured indirectly
acid group, but was unchanged in the placebo group. by dual-energy x-ray absorptiometry of the cancellous
Furthermore, BMD of the lumbar spine increased by vertebrae in comparison to the dual-energy x-ray absorp-
31% in the bisphosphonate group, but deteriorated fur- tiometry readings of the cortical femur neck. However,
ther by 38% (z score) in the placebo group, although the trabecular mineralization and architecture are more
all patients were treated concomitantly with 1000 mg important for the stability and performance of the bone
calcium citrate daily. than cortical mineralization [34]. To further analyze the
It has been shown previously that vitamin D, calcito- influence of zoledronic acid on cancellous bone, we used
nin, estrogen, or testosterone supplementation is ineffec- several methods. Besides dual-energy x-ray absorptiome-
tive in preventing post-transplant bone loss [26–30]. try, which, due the high absorption of the cortical layer,
Older generation bisphosphonates could not prevent is, in particular, insufficient in femoral cancellous bone
early post-transplant bone loss, but exhibited benefits density measurement, we additionally determined min-
from 1 year on in preventing further deterioration of eralization density distribution and morphometry of bone
existing bone disease [26, 27]. Newer generation bisphos- biopsies. The main finding in the current investigation
phonates, such as pamidronate and ibandronate, are was the significant increase of Camean, a very sensitivemore potent than first-generation bisphosphonates on
measure of trabecular mineralization with low interindi-
an equimolar basis and can prevent the loss in BMD after
vidual variation of results [12]. This result of increasedtransplantation [31, 32]. Similar results were obtained in
Camean is in accordance with previous studies on humanthe present study with zoledronic acid. The placebo
and animal bone bisphosphonate treatment [13, 14]. Thegroup patients experienced a reduction in cancellous
measured increase of calcium content was confirmed bybone density, and zoledronic acid-treated patients exhib-
significantly lower serologic markers specific for boneited an increase in lumbar spine mineral density in dual-
formation (osteocalcin) and increased bone resorptionenergy x-ray absorptiometry studies. However, an in-
[type I collagen peptides (crosslaps)] in treated patients.crease in densitometry scores does not necessarily mean
Biochemical markers of high-turnover osteopathy, suchhigher bone stability. Logistic regression analysis showed
as iPTH, improved in both treatment groups within theonly a weak association between BMD and fracture risk.
first 6 months after transplantation, mirroring the histo-Per z score unit increase in spine BMD, the odds ratio
morphologic changes that result from adequate renalof developing a fracture within a median of 5 years was
transplant function.1.57 (1.04 to 2.37, 95% CI) in nontransplanted patients
[33]. One of the main determinants of bone strength is
bone architecture [34]. Because randomized studies of CONCLUSION
post-transplant osteopathy in renal patients with fracture
In conclusion, this is the first study to show that postrate as end point are unlikely to be conducted, treatment
transplant administration of zoledronic acid not only con-success with regards to changes in bone architecture (mi-
ferred an increase of bone mineralization but, that despitecromorphology) can only be evaluated by quantitative
the use of high steroid doses, trabecular calcium contenthistomorphometry of bone biopsy cores. The present
increased and cancellous bone could be stabilized.study is the first to show that the new-generation bisphos-
phonate zoledronic acid led to an increase of osteoid
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